+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review

Merck & Co Inc (MRK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Merck & Co Inc (Merck) is a biopharmaceutical company that discovers, develops, manufactures, and markets medicines, vaccines, biologic therapies, and animal health products. The company offers prescription medicines under the therapy areas of oncology, vaccines, infectious diseases, cardio-metabolic disorders, immunology, neuroscience, and ophthalmology. It also offers a wide range of veterinary pharmaceuticals; vaccines; health management solutions and services; and identification, traceability, and monitoring products. Merck’s products are provided to drug wholesalers, retailers, hospitals, government agencies, health maintenance organizations, pharmacy benefit managers, other institutions, veterinarians, distributors, animal producers, farmers, and pet owners. It operates manufacturing facilities in North America, South America, Western Europe, Africa, and Asia. Merck is headquartered in Rahway, New Jersey, the US.

Merck & Co Inc Key Recent Developments

  • Apr 30, 2026: Merck & Co Announces First-Quarter 2026 Financial Results and Clinical Milestones
  • Apr 23, 2026: MSD teams up with Google Cloud on agentic AI transformation
  • Apr 20, 2026: MSD secures EC approval for Enflonsia to prevent infant RSV infection
  • Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Merck & Co Inc - Key Facts
  • Merck & Co Inc - Key Employees
  • Merck & Co Inc - Key Employee Biographies
  • Merck & Co Inc - Major Products and Services
  • Merck & Co Inc - History
  • Merck & Co Inc - Company Statement
  • Merck & Co Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Merck & Co Inc - Business Description
  • Business Segment: Animal Health
  • Overview
  • Performance
  • Business Segment: Other
  • Overview
  • Performance
  • Business Segment: Pharmaceutical
  • Overview
  • Performance
  • Geographical Segment: Asia Pacific (other than China and Japan)
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: Europe, Middle East and Africa
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Latin America
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Merck & Co Inc - Corporate Strategy
  • Merck & Co Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Merck & Co Inc - Strengths
  • Merck & Co Inc - Weaknesses
  • Merck & Co Inc - Opportunities
  • Merck & Co Inc - Threats
  • Merck & Co Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Merck & Co Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 30, 2026: Merck & Co Announces First-Quarter 2026 Financial Results and Clinical Milestones
  • Apr 23, 2026: MSD teams up with Google Cloud on agentic AI transformation
  • Apr 20, 2026: MSD secures EC approval for Enflonsia to prevent infant RSV infection
  • Apr 15, 2026: Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics
  • Apr 13, 2026: Ifinatamab Deruxtecan Granted Priority Review in U.S. for Adults With Previously Treated Extensive-Stage Small Cell Lung Cancer
  • Apr 01, 2026: Merck to Hold Q1 2026 Sales and Earnings Conference Call on April 30
  • Mar 29, 2026: Positive Phase 2 CADENCE Data Provide Proof-of-Concept for Merck’s WINREVAIR in Adults With Combined Post- and Precapillary Pulmonary Hypertension and HFpEF
  • Mar 25, 2026: MSD and Quotient collaborate on IBD drug targets
  • Mar 18, 2026: FDA Approves BRAVECTO QUANTUM Injectable From Merck Animal Health to Treat Asian Longhorned and Gulf Coast Ticks for 12 Months in Dogs
  • Mar 16, 2026: Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Merck & Co Inc, Key Facts
  • Merck & Co Inc, Key Employees
  • Merck & Co Inc, Key Employee Biographies
  • Merck & Co Inc, Major Products and Services
  • Merck & Co Inc, History
  • Merck & Co Inc, Subsidiaries
  • Merck & Co Inc, Joint Venture
  • Merck & Co Inc, Key Competitors
  • Merck & Co Inc, Ratios based on current share price
  • Merck & Co Inc, Annual Ratios
  • Merck & Co Inc, Interim Ratios
  • Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Merck & Co Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Merck & Co Inc, Performance Chart (2021-2025)
  • Merck & Co Inc, Ratio Charts
  • Merck & Co Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Merck & Co Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Novartis AG
  • AbbVie Inc
  • Bristol-Myers Squibb Co
  • Sanofi
  • Amgen Inc
  • Roche Holding AG
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • Pfizer Inc
  • Incyte Corp
  • Hester Biosciences Ltd
  • Eli Lilly and Co